Title Image

Improving people’s lives with innovative technologies: Dynamic42 receives funding from the iDEA-iTECH Award

Sanofi iDEA-iTECH Awards 2023

Improving people’s lives with innovative technologies: Dynamic42 receives funding from the iDEA-iTECH Award

We are pleased to announce that Dynamic42 is one of the chosen companies and research groups receiving funding from of the Sanofi iDEA-iTECH Award. The initiative supports innovators in North America and Europe to develop breakthrough digital technologies and data analytics tools to create transformative solutions and processes that have the potential to improve people’s lives. Together with Sanofi, we will work to implement organ-on-chip technology for DMPK assays.

YouTube: Sanofi iDEA-iTECH Awards 2023

About the planned project with DMPK assays

DMPK stands for “Drug Metabolism and Pharmacokinetics” and refers to the study of the pharmacological properties of drugs. This includes e.g. research into the absorption, distribution, metabolization and excretion of a drug in the body. DMPK assays are an important part of drug development as they allow the assessment of drug efficacy and safety.

 

DMPK assays are used, for example, to determine optimal drug dosages or to identify adverse effects and toxicities of drugs. The implementation of organ-on-chip technology is expected to improve the precision and predictability of these assays and thus increase the efficiency of drug development. Scientists will be able to study the interactions between drugs and human cells more precisely and identify potential toxicities or efficacy problems earlier in the development process. Dynamic42s biotech chips and organ-on-chip technology will thus explicitly contribute to the improvement of investigation and analysis processes in the future.

Sanofi iDEA-iTECH Awards program

The collaboration with Sanofi in the iDEA-iTECH Awards Programme offers Dynamic42 the opportunity to expand our expertise in this field and explore new areas of application. The programme also focuses on mutual support and exchange with Sanofi experts as well as other scientists. For us, the collaboration means being able to further optimise our technology,  processes and consolidate our position as part of the drug development process.

 

Martin Raasch, CEO of Dynamic42, emphasises the importance of this collaboration: “Together with Sanofi, we are eager to explore new areas of application and drive possible further developments.” We look forward to the cooperation and are excited about future developments.

More interesting articles:

Blog

Brief summary on our work focusing on the development of a sophisticated intestine-on-chip model to study fungal infections, particularly candidiasis.

Read More
Blog

One crucial factor that plays a pivotal role in the success of organ-on-cip models is immunocompetence. In this blog post, we delve into the significance of immunocompetence in organ-on-chip models and how it opens new avenues for advancing medical research.

Read More
Blog

Learn the skills to integrate organ-on-chip technology into your lab work with the Dynamic42 Academy. If this resonates with you, this blog will help you to understand if our organ-on-chip class is for you. We will give you a deep dive into the reasons to attend our course, what we teach in the course, and what past participants have to say.

Read More